BTIG analyst Marie Thibault maintained a Buy rating on Irhythm Technologies (IRTC – Research Report) yesterday and set a price target of $132.00. The company’s shares closed last Friday at $107.04.
According to TipRanks, Thibault is an analyst with an average return of -1.8% and a 35.26% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Inari Medical, Atricure, and Insulet.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Irhythm Technologies with a $123.60 average price target, representing a 15.47% upside. In a report released on December 21, Canaccord Genuity also maintained a Buy rating on the stock with a $121.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $140.23 and a one-year low of $70.24. Currently, Irhythm Technologies has an average volume of 363.2K.
Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IRTC in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Irhythm Technologies (IRTC) Company Description:
iRhythm Technologies, Inc. is a commercial-stage digital healthcare company, which engages in the development of monitoring and diagnostic solutions for detection of cardiac arrhythmias. It offers ZIO which diagnose many arrhythmias, avoiding multiple indeterminate tests, allowing for appropriate medical intervention, and prevents serious downstream medical events. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA.
Read More on IRTC:
- iRhythm Technologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- iRhythm price target raised by $15 at Truist, here’s why
- Citi entering 2024 ‘cautiously optimistic’ on U.S. MedTech companies
- iRhythm just upgraded at Citi, here’s why
- Citi gets more bullish on iRhythm, upgrades shares
